Summary
To support the global community in its fight against the ongoing COVID-19 pandemic, G42 Healthcare commenced the world's first phase III clinical trial of an inactivated COVID-19 vaccine in July 2020. The phase III clinical trial considers the safety in the UAE alone. With only a few days from concept development to launch, G42 Healthcare and APCO mobilized their efforts across communications, media relations, crisis management, digital, social media, campaign identity, and on-ground branding to prepare for the launch and welcome the first volunteers.
